Rapid relapse of idiopathic multicentric Castleman disease after siltuximab discontinuation in a case with complete remission for more than 10 years

in the management of iMCD is crucial, and any attempts to discontinue its use should be approached with caution and probably avoided.Third, for patients who have exhibited a favorable response to siltuximab, its efficacy remains consistent upon re-administration, confirming the feasibility and efficacy of reusing the drug as a therapeutic approach in such cases.